The Journal of Bone and Joint Surgery 79:1365-72 (1997)
© 1997 The Journal of Bone and Joint Surgery, Inc.
Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty. Comparison of Warfarin and Dalteparin*
CHARLES W. FRANCIS, M.D. , ROCHESTER,
VINCENT D. PELLEGRINI, JR., M.D. , HERSHEY, PENNSYLVANIA,
SAARA TOTTERMAN, M.D. ,
ALLEN D. BOYD, JR., M.D. ,
VICTOR J. MARDER, M.D. ,
KRISTIN M. LIEBERT, M.A. , ROCHESTER, NEW YORK,
BERNARD N. STULBERG, M.D. , CLEVELAND, OHIO,
DAVID C. AYERS, M.D.¶, SYRACUSE, NEW YORK,
AARON ROSENBERG, M.D.#, CHICAGO, ILLINOIS,
CRAIG KESSLER, M.D.**, WASHINGTON, D.C. and
NORMAN A. JOHANSON, M.D. , PHILADELPHIA, PENNSYLVANIA
Investigation performed at University of Rochester School of Medicine, Rochester; The Milton S. Hershey Medical Center, Hershey; Cleveland Center for Joint Reconstruction, Cleveland; State University of New York Health Science Center at Syracuse, Syracuse; Rush-Presbyterian-St. Luke's Medical Center, Chicago; George Washington University Medical Center, Washington, D.C.; and Temple University School of Medicine, Philadelphia
The effectiveness and safety of warfarin were compared with those of a low-molecular-weight heparin (dalteparin) for the prevention of deep-vein thrombosis after total hip arthroplasty in a prospective, randomized, multi-institutional trial. Patients who were older than eighteen years of age and were scheduled to have an elective primary or revision total hip arthroplasty were eligible; 580 patients were randomized, 550 had the operation and received prophylaxis, and 382 had evaluable venograms. Prophylaxis was provided either with warfarin beginning the night before the operation or with dalteparin beginning two hours before the operation and was continued until venography was performed. Bleeding was assessed on the basis of intraoperative blood loss, transfusion requirements, a decrease in hematocrit, and clinically identified bleeding complications.
The prevalence of deep-vein thrombosis was found to be significantly lower in the patients who had received dalteparin than in those who had received warfarin (twenty-eight [15 per cent] of 192 patients compared with forty-nine [26 per cent] of 190 patients; p = 0.006). Deep-vein thrombosis occurred in the calf veins of twenty-one patients (11 per cent) who had received dalteparin and of forty-three patients (23 per cent) who had received warfarin; this difference was significant (p = 0.003). Proximal deep-vein thrombosis occurred in ten patients (5 per cent) who had received dalteparin and in sixteen patients (8 per cent) who had received warfarin; however, with the numbers available, no significant difference could be detected (p = 0.185). We also could not detect a significant difference with regard to the intraoperative and postoperative blood loss, the decrease in hematocrit, and the prevalence of major bleeding complications between the two groups; however, the patients who had received dalteparin had a significantly higher prevalence of bleeding complications involving the operative site (p = 0.03), and a significantly greater percentage required postoperative transfusions (p = 0.001).
We concluded that preoperative prophylaxis with dalteparin is significantly more effective than that with warfarin in preventing deep-vein thrombosis after total hip arthroplasty. The greater effectiveness of dalteparin must be considered, however, in light of an increased need for postoperative transfusions and an increase in the prevalence of wound-related bleeding complications.

CiteULike Connotea Del.icio.us Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. B. Haas, R. L. Barrack, G. Westrich, and P. F. Lachiewicz
Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am.,
December 1, 2008;
90(12):
2764 - 2780.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A Nutescu, A. F Shorr, E. Farrelly, R. Horblyuk, L. E Happe, and M. Franklin
Burden of Deep Vein Thrombosis in the Outpatient Setting Following Major Orthopedic Surgery
Ann. Pharmacother.,
September 1, 2008;
42(9):
1216 - 1221.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Dorr, V. Gendelman, A. V. Maheshwari, M. Boutary, Z. Wan, and W. T. Long
Multimodal Thromboprophylaxis for Total Hip and Knee Arthroplasty Based on Risk Assessment
J. Bone Joint Surg. Am.,
December 1, 2007;
89(12):
2648 - 2657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V Bagaria, N Modi, A Panghate, and S Vaidya
Incidence and risk factors for development of venous thromboembolism in Indian patients undergoing major orthopaedic surgery: results of a prospective study
Postgrad. Med. J.,
February 1, 2006;
82(964):
136 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Lieberman and W. K. Hsu
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am.,
September 1, 2005;
87(9):
2097 - 2112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Agnelli
Prevention of Venous Thromboembolism in Surgical Patients
Circulation,
December 14, 2004;
110(24_suppl_1):
IV-4 - IV-12.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. McGuire and P. P. Dobesh
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
Journal of Pharmacy Practice,
October 1, 2004;
17(5):
289 - 307.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Hilty
Update in Perioperative Medicine
Ann Intern Med,
September 21, 2004;
141(6):
486 - 486.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
338S - 400S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A Nutescu, R. K Lewis, J. M Finley, and G. T Schumock
Hospital Guidelines for Use of Low-Molecular-Weight Heparins
Ann. Pharmacother.,
July 1, 2003;
37(7):
1072 - 1081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Hull and A. F. Mah
Reporting the NAFT Major Bleeding Rates in Context: Reviewers Should Include Site Investigator-Classified Rates
Arch Intern Med,
February 10, 2003;
163(3):
369 - 369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. W. Francis, B. L. Davidson, S. D. Berkowitz, P. A. Lotke, J. S. Ginsberg, J. R. Lieberman, A. K. Webster, J. P. Whipple, G. R. Peters, and C. W. Colwell Jr.
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty: A Randomized, Double-Blind Trial
Ann Intern Med,
October 15, 2002;
137(8):
648 - 655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Prandoni, O. Bruchi, P. Sabbion, C. Tanduo, A. Scudeller, C. Sardella, G. Errigo, F. Pietrobelli, G. Maso, and A. Girolami
Prolonged Thromboprophylaxis With Oral Anticoagulants After Total Hip Arthroplasty: A Prospective Controlled Randomized Study
Arch Intern Med,
September 23, 2002;
162(17):
1966 - 1971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Whang and J. R. Lieberman
Low-Molecular-Weight Heparin
J. Am. Acad. Ortho. Surg.,
September 1, 2002;
10(5):
299 - 302.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Strebel, M. Prins, G. Agnelli, and H. R. Buller
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
Arch Intern Med,
July 8, 2002;
162(13):
1451 - 1456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Douketis, J. W. Eikelboom, D. J. Quinlan, A. R. Willan, and M. A. Crowther
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement: A Meta-analysis of Prospective Studies Investigating Symptomatic Outcomes
Arch Intern Med,
July 8, 2002;
162(13):
1465 - 1471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Murashige, M. Kami, S. Marlovits, M. Priestley, R. Scacewater, B. I. Eriksson, and D. L. Diuguid
Prevention of Venous Thromboembolism with Fondaparinux
N. Engl. J. Med.,
March 21, 2002;
346(12):
940 - 942.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. P. Sculco, C. W. Colwell Jr., V. D. Pellegrini Jr., G. H. Westrich, and F. Bottner
Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty
J. Bone Joint Surg. Am.,
March 1, 2002;
84(3):
466 - 477.
[Full Text]
|
 |
|

|
 |

|
 |
 
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, M. Butcher, R. F. Brant, W. A. Ghali, D. Bergqvist, et al.
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review
Ann Intern Med,
November 20, 2001;
135(10):
858 - 869.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, W. A. Ghali, M. S. Butcher, R. F. Brant, D. Bergqvist, et al.
Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review
Arch Intern Med,
September 10, 2001;
161(16):
1952 - 1960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hull, G. Pineo, L. Landow, A. G.G. Turpie, A. S. Gallus, and J. A. Hoek
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis
N. Engl. J. Med.,
July 26, 2001;
345(4):
291 - 292.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Bajjoka, R. Hull, G. Pineo, C. Francis, D. Bergqvist, C. Fellenius, A. Mah, and R. Brant
Dalteparin vs Warfarin in Hip Arthroplasty Patients
Arch Intern Med,
March 12, 2001;
161(5):
776 - 777.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Hakki, J. Fareed, D. A. Hoppensteadt, H. Abdullah, J. Camblin, A. F. Nasseri, O. Hamadeh, and T. Wright
Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2001;
7(1):
65 - 71.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler
Prevention of Venous Thromboembolism
Chest,
January 1, 2001;
119(1_suppl):
132S - 175S.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Hakki, J. Fareed, D. A. Hoppensteadt, H. Abdullah, J. Camblin, A. F. Nasseri, O. Hamadeh, and T. Wright
Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2000;
6(4):
206 - 212.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al.
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Arch Intern Med,
July 24, 2000;
160(14):
2199 - 2207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al.
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Arch Intern Med,
July 24, 2000;
160(14):
2208 - 2215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. B. Freedman, K. R. Brookenthal, R. H. Fitzgerald, S. Williams, and J. H. Lonner
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty
J. Bone Joint Surg. Am.,
July 1, 2000;
82(7):
929 - 929.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. A. SALVATI, V. D. PELLEGRINI, N. E. SHARROCK, P. A. LOTKE, D. W. MURRAY, H. POTTER, and G. H. WESTRICH
Symposium - Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement
J. Bone Joint Surg. Am.,
February 1, 2000;
82(2):
252 - 70.
[Full Text]
|
 |
|

|
 |

|
 |
 
O. LEVY, U. MARTINOWITZ, A. ORAN, C. TAUBER, and H. HOROSZOWSKI
The Use of Fibrin Tissue Adhesive to Reduce Blood Loss and the Need for Blood Transfusion After Total Knee Arthroplasty. A Prospective, Randomized, Multicenter Study
J. Bone Joint Surg. Am.,
November 1, 1999;
81(11):
1580 - 8.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
LMWH VS. WARFARIN TO PREVENT DVT AFTER HIP REPLACEMENT
Journal Watch (General),
October 17, 1997;
1997(1017):
1 - 1.
[Full Text]
|
 |
|
|